PTC Therapeutics Inc

PTC Therapeutics Inc. a biopharmaceutical company focuses on the discovery development and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development including clinical pre-clinical and research and discovery stages focuses on the development of treatments for multiple therapeutic areas such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518 which is being developed for the treatment of Huntington's disease; bio-e platform such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform including an asset targeting Friedreich ataxia; oncology platform such as Unesbulin; and other multi-platform. PTC Therapeutics Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics Inc. was incorporated in 1998 and is headquartered in South Plainfield New Jersey.